These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
178 related articles for article (PubMed ID: 24982850)
1. Beyond hepatocellular carcinoma and colorectal metastasis: the expanding applications of radioembolization. Zurkiya O; Ganguli S Front Oncol; 2014; 4():150. PubMed ID: 24982850 [TBL] [Abstract][Full Text] [Related]
2. 90Y Radioembolization Lung Shunt Fraction in Primary and Metastatic Liver Cancer as a Biomarker for Survival. Xing M; Lahti S; Kokabi N; Schuster DM; Camacho JC; Kim HS Clin Nucl Med; 2016 Jan; 41(1):21-7. PubMed ID: 26222534 [TBL] [Abstract][Full Text] [Related]
4. SIR-Spheres yttrium-90 radioembolization for the treatment of unresectable liver cancers. Golfieri R Hepat Oncol; 2014 Jun; 1(3):265-283. PubMed ID: 30190962 [TBL] [Abstract][Full Text] [Related]
5. Radioembolization for the Treatment of Primary and Metastatic Liver Cancers. Lee EJ; Chung HW; Jo JH; So Y Nucl Med Mol Imaging; 2019 Dec; 53(6):367-373. PubMed ID: 31867071 [TBL] [Abstract][Full Text] [Related]
6. State of the art: radiolabeled microspheres treatment for liver malignancies. Deleporte A; Flamen P; Hendlisz A Expert Opin Pharmacother; 2010 Mar; 11(4):579-86. PubMed ID: 20163269 [TBL] [Abstract][Full Text] [Related]
7. Current status of transarterial radioembolization. Mahnken AH World J Radiol; 2016 May; 8(5):449-59. PubMed ID: 27247711 [TBL] [Abstract][Full Text] [Related]
8. Metastatic disease to the liver: Locoregional therapy strategies and outcomes. Zane KE; Cloyd JM; Mumtaz KS; Wadhwa V; Makary MS World J Clin Oncol; 2021 Sep; 12(9):725-745. PubMed ID: 34631439 [TBL] [Abstract][Full Text] [Related]
10. Tc-99m-MAA lung shunt fraction before Y-90 radioembolization is low among patients with non-hepatocellular carcinoma malignancies. Elsayed M; Martin JG; Dabrowiecki A; Goldman DT; Faraj R; McMahon JT; Kokabi N; Duszak R; Newsome J; Bercu ZL Nucl Med Commun; 2019 Nov; 40(11):1154-1157. PubMed ID: 31568192 [TBL] [Abstract][Full Text] [Related]
11. Radioembolization in the treatment of unresectable liver tumors: experience across a range of primary cancers. Coldwell D; Sangro B; Salem R; Wasan H; Kennedy A Am J Clin Oncol; 2012 Apr; 35(2):167-77. PubMed ID: 21127414 [TBL] [Abstract][Full Text] [Related]
12. Radioembolization (yttrium-90 microspheres) for primary and metastatic hepatic malignancies. Kennedy AS; Salem R Cancer J; 2010; 16(2):163-75. PubMed ID: 20404614 [TBL] [Abstract][Full Text] [Related]
13. Yttrium-90 Radioembolization for Metastatic Colorectal Cancer: Outcomes by Number of Lines of Therapy. Marsala A; Lee EW; Padia SA Semin Intervent Radiol; 2017 Jun; 34(2):116-120. PubMed ID: 28579679 [TBL] [Abstract][Full Text] [Related]
18. Pilot study of angiogenic response to yttrium-90 radioembolization with resin microspheres. Carpizo DR; Gensure RH; Yu X; Gendel VM; Greene SJ; Moore DF; Jabbour SK; Nosher JL J Vasc Interv Radiol; 2014 Feb; 25(2):297-306.e1. PubMed ID: 24360887 [TBL] [Abstract][Full Text] [Related]
19. History and Evolution of Yttrium-90 Radioembolization for Hepatocellular Carcinoma. Saini A; Wallace A; Alzubaidi S; Knuttinen MG; Naidu S; Sheth R; Albadawi H; Oklu R J Clin Med; 2019 Jan; 8(1):. PubMed ID: 30621040 [TBL] [Abstract][Full Text] [Related]
20. The Role of Radioembolization in Bridging and Downstaging Hepatocellular Carcinoma to Curative Therapy. Titano J; Voutsinas N; Kim E Semin Nucl Med; 2019 May; 49(3):189-196. PubMed ID: 30954184 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]